(Q30342038)

20 June 2017

1 reference

title

Prospects for an AIDS vaccine: three big questions, no easy answers. (English)

1 reference

20 June 2017

1 reference

2

Guido Silvestri

1 reference

20 June 2017

David A Garber

1

1 reference

PubMed ID

15219551

20 June 2017

Mark B Feinberg

series ordinal

3

1 reference

20 June 2017

1 July 2004

1 reference

Lancet Infectious Diseases

20 June 2017

1 reference

20 June 2017

4

1 reference

20 June 2017

7

1 reference

20 June 2017

397-413

1 reference

Public health. AIDS vaccine trial produces disappointment and confusion

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

AIDS vaccines: back to 'plan A'.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

New hope for an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Toward an understanding of the correlates of protective immunity to HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Prospects for an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Viral persistence: HIV's strategies of immune system evasion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Virology. HIV may shed some protection as it jumps to new hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

CCR5 mimicry by sulfated human anti-HIV-1 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-1 neutralizing antibodies: how full is the bottle?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Evolutionary and immunological implications of contemporary HIV-1 variation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Functional genomics Double-stranded RNA poses puzzle

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Multifactorial nature of noncytolytic CD8+ T cell-mediated suppression of HIV replication: beta-chemokine-dependent and -independent effects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

The challenge of viral reservoirs in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

The influence of HLA genotype on AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Quantifying the uncertainty in forecasts of anthropogenic climate change

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

T cell responses and viral escape

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Escape of human immunodeficiency virus from immune control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

AIDS vaccine models: challenging challenge viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV escape: there and back again

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

The dynamics of CD4+ T-cell depletion in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Skewed maturation of memory HIV-specific CD8 T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Lineage relationship and protective immunity of memory CD8 T cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Viral immune evasion due to persistence of activated T cells without effector function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Immunologic profile of highly exposed yet HIV type 1-seronegative men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV preferentially infects HIV-specific CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Control of SIV rebound through structured treatment interruptions during early infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

A patient with HIV-1 superinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Immunology. CD8 T cells remember with a little help

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

The role of programming in memory T-cell development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Memory CD8 T-cell differentiation during viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Molecular and functional profiling of memory CD8 T cell differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Effector and memory T-cell differentiation: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Dynamics of HIV-1 recombination in its natural target cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Diversity considerations in HIV-1 vaccine selection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV/AIDS. HLA leaves its footprints on HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Immune control of HIV: the obstacles of HLA and viral diversity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Gradual adaptation of HIV to human host populations: good or bad news?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV evolution: CTL escape mutation and reversion after transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Reversion of CTL escape–variant immunodeficiency viruses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Policy rebuttal. HIV vaccine trial justified.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

HIV/AIDS. Vaccine results lose significance under scrutiny

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Public health. AIDS vaccine still alive as booster after second failure in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Disappointing data scuttle plans for large-scale AIDS vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Alphavirus replicon particles as candidate HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

The prime-boost strategy: exciting prospects for improved vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Endpoints in vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

On the analysis of viral load endpoints in HIV vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Public health. Grand Challenges in Global Health

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

Medicine. The need for a global HIV vaccine enterprise

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901056-4

7 January 2021

10.1016/S1473-3099(04)01056-4

Identifiers

DOI

1 reference

20 June 2017

1 reference

PubMed ID

15219551